Loading…
Loading…
Robotics is entering a new era as AI fuels humanoid adoption, with four ETFs offering diversified exposure to the sector's growth.
Connor Clark and Lunn Investment Management Ltd. acquired a new position in Novanta Inc. (NASDAQ: NOVT) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 4,845 shares of the technology company's stock, valued at approximately $786,000. Several other large investors have
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, and John Lesica, Chief Operating Officer of Medical Solutions, are scheduled to present at the Baird Global Healthcare Conference on Tuesday, September 15, 2026, in New York, NY. About Novanta Novanta is a leading global supplier of core technology solutions that give medical a.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Novanta (NOVT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Does Novanta (NOVT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Bank of America Corp DE increased its stake in Novanta Inc. (NASDAQ: NOVT) by 18.3% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 456,241 shares of the technology company's stock after acquiring an additional 70,728 shares during the
Amundi increased its position in shares of Novanta Inc. (NASDAQ: NOVT) by 17.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 23,187 shares of the technology company's stock after buying an additional 3,516 shares during the quarter. Amundi owned 0.07% of
Novanta (NASDAQ: NOVT) reported second-quarter results marked by 9% organic sales growth, expanding margins and higher operating cash flow, while raising its full-year outlook following the late-July closing of its Riverpoint Medical acquisition. Chair and Chief Executive Officer Matthijs Glastra said reported revenue grew 10% year over year during the quarter, while adjusted EBITDA increased 16%